39 results about "Drug pharmacokinetics" patented technology

A microfluidic device for culturing cells, termed a microscale cell culture analog (μCCA), is provided. The microfluidic device allows multiple cell or tissue types to be cultured in a physiologically relevant environment, facilitates high-throughput operation and can be used for drug discovery. The microfluidic device uses gravity-induced fluidic flow, eliminating the need for a pump and preventing formation of air bubbles. Reciprocating motion between a pair of connected reservoirs is used to effect the gravity-induced flow in microfluidic channels. Bacterial contamination is reduced and high throughput enabled by eliminating a pump. The microfluidic device integrates a pharmacokinetic-pharmacodynamic (PK-PD) model to enable PK-PD analyses on-chip. This combined in vitro / in silico system enables prediction of drug toxicity in a more realistic manner than conventional in vitro systems.

A method of using Raman imaging microscopy to evaluate drug actions in living cells is disclosed. Specifically the invention describes the methods of using Raman imaging microscopy to detect drug uptake, distribution, binding, and metabolism in a single cell, and to study drug pharmacokinetics at the cellular level. The method involves measuring the Raman image of both the drug and the cell. Control images and post-treatment images of the cell were studied. Ratio images were calculated and the requisite information was obtained from a study of the intensity of the bright areas in the ratio images.

Methods and devices for administration of substances into at least two compartments of skin for systemic absorption and improved pharmacokinetics, based on biphasic or bimodel kinetic profiling.

The invention provides a method for catalytic conversion of a cyano group into deuterated methyl, a prepared aromatic deuterated methyl compound and an application of the compound. The method comprises the steps as follows: an aromatic cyano compound reacts to produce the aromatic deuterated methyl compound under the action of a metal catalyst with deuterium gas serving as a deuterium source. The cyano group is directly catalyzed into deuterated methyl with the deuterium gas serving as the deuterium source, the operation is simple, the raw material is cheap and easy to obtain, the reaction yield is high, the product deuteration rate is high, and the method can be applied to mass production. The prepared aromatic deuterated methyl compound can be used as a deuterated medicine or can be used for preparation of a deuterated medicine or deuterated medicine composition, and the pharmacokinetics, pharmacodynamics or metabolism toxicity of the medicine can be reduced while the medicine molecular activity is kept unchanged basically.

The invention discloses a reduction-responsive targeted polyethylene glycol-polycarbonate maytansine prodrug micelle, a preparation method and application thereof. The amphiphilic polyethylene glycol-polycarbonate maytansinoid prodrug polymer composed of amphiphilic polyethylene glycol-polycarbonate maytansinoid prodrug polymer and the terminal-bonded targeting molecule were automatically activated in buffer. Targeted polyethylene glycol-polycarbonate maytansine prodrug micelles with reduction response were assembled; the particle size of the micelles was 30-150 nanometers, and the drug-loading capacity of maytansine was 2-60 wt .%. The reduction-responsive targeted polycarbonate maytansinoid prodrug micelles provided by the present invention have targeting properties, amphiphilicity and biodegradability, and nano-medicines can be prepared therefrom, which can significantly improve the water-solubility of drugs and enhance drug Stability in circulation process, improvement of drug pharmacokinetic behavior and improvement of drug bioavailability; it can be applied in the preparation of malignant tumors such as targeted therapy drugs for melanoma.

The present invention relates to aryl linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

The invention relates to a system used in the internal dynamic nondestructive online checking of protein polypeptide drug, and relative checking method. The inventive system comprises a fluorescence probe and a detecting system, while the detecting system is formed by a near-infrared light source, a transmission optical fiber, a receiving optical fiber, a near-infrared high-pass filter, and a near-infrared detector. The laser of light source and the fluorescence light received by the detector can be transmitted by the optical fiber; the near-infrared band-pass or high-pass filter is at the front of detector. The invention can avoid sampling timely in the test, avoid killing animals in the organism distribution test, to and avoid the following sample treatment.